Tadalafil Promotes the Recovery of Peripheral Neuropathy in Type II Diabetic Mice
Recommended Citation
Wang L, Chopp M, Szalad A, Lu X, Jia L, Lu M, Zhang RL, and Zhang ZG. Tadalafil promotes the recovery of peripheral neuropathy in type II diabetic mice. PLoS One 2016; 11(7):e0159665.
Document Type
Article
Publication Date
1-1-2016
Publication Title
PLoS One
Abstract
We previously demonstrated that treatment of diabetic peripheral neuropathy with the short (4 hours) half-life phosphodiesterase 5 (PDE5) inhibitor, sildenafil, improved functional outcome in diabetic db/db mice. To further examine the effect of PDE5 inhibition on diabetic peripheral neuropathy, we investigated the effect of another potent PDE5 inhibitor, tadalafil, on diabetic peripheral neuropathy. Tadalafil is pharmacokinetically distinct from sildenafil and has a longer half-life (17+hours) than sildenafil. Diabetic mice (BKS.Cg-m+/+Leprdb/J, db/db) at age 20 weeks were treated with tadalafil every 48 hours for 8 consecutive weeks. Compared with diabetic mice treated with saline, tadalafil treatment significantly improved motor and sensory conduction velocities in the sciatic nerve and peripheral thermal sensitivity. Tadalafil treatment also markedly increased local blood flow and the density of FITC-dextran perfused vessels in the sciatic nerve concomitantly with increased intraepidermal nerve fiber density. Moreover, tadalafil reversed the diabetes-induced reductions of axon diameter and myelin thickness and reversed the diabetes-induced increased g-ratio in the sciatic nerve. Furthermore, tadalafil enhanced diabetes-reduced nerve growth factor (NGF) and platelet-derived growth factor-C (PDGF-C) protein levels in diabetic sciatic nerve tissue. The present study demonstrates that tadalafil increases regional blood flow in the sciatic nerve tissue, which may contribute to the improvement of peripheral nerve function and the amelioration of diabetic peripheral neuropathy.
Medical Subject Headings
Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Disease Models, Animal; Gene Expression Regulation; Humans; Lymphokines; Mice; Mice, Inbred NOD; Motor Activity; Nerve Fibers; Nerve Growth Factor; Peripheral Nervous System Diseases; Platelet-Derived Growth Factor; Sciatic Nerve; Tadalafil
PubMed ID
27438594
Volume
11
Issue
7
First Page
e0159665